A human antibody potently neutralizes RSV by targeting the conserved hydrophobic region of prefusion F

[1]  Jun Zhang,et al.  Current progress in the development of prophylactic and therapeutic vaccines , 2022, Science China Life Sciences.

[2]  Z. Ling,et al.  Broad strategies for neutralizing SARS-CoV-2 and other human coronaviruses with monoclonal antibodies , 2022, Science China Life Sciences.

[3]  R. Rappuoli,et al.  The respiratory syncytial virus (RSV) prefusion F‐protein functional antibody repertoire in adult healthy donors , 2021, EMBO molecular medicine.

[4]  Chaim A. Schramm,et al.  Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responses. , 2021, Immunity.

[5]  R. Kane,et al.  The Design of Vaccines Based on the Shielding of Antigenic Site Ø of a Respiratory Syncytial Virus Fusion Protein Immunogen , 2020, Advanced healthcare materials.

[6]  N. Petrovsky,et al.  Prefusion RSV F Immunization Elicits Th2-Mediated Lung Pathology in Mice When Formulated With a Th2 (but Not a Th1/Th2-Balanced) Adjuvant Despite Complete Viral Protection , 2020, Frontiers in Immunology.

[7]  Rongguang Zhang,et al.  Junctional and somatic hypermutation-induced CX4C motif is critical for the recognition of a highly conserved epitope on HCV E2 by a human broadly neutralizing antibody , 2020, Cellular & Molecular Immunology.

[8]  S. Kazer,et al.  Germline-Encoded Affinity for Cognate Antigen Enables Vaccine Amplification of a Human Broadly Neutralizing Response against Influenza Virus. , 2019, Immunity.

[9]  H. Su,et al.  Characterization of potent RSV neutralizing antibodies isolated from human memory B cells and identification of diverse RSV/hMPV cross-neutralizing epitopes , 2019, mAbs.

[10]  E. Saphire,et al.  Convergent Structures Illuminate Features for Germline Antibody Binding and Pan-Lassa Virus Neutralization , 2019, Cell.

[11]  J. McLellan,et al.  Alternative conformations of a major antigenic site on RSV F , 2019, PLoS pathogens.

[12]  J. McLellan,et al.  Respiratory syncytial virus entry and how to block it , 2019, Nature Reviews Microbiology.

[13]  H. Nair,et al.  Antigenic and sequence variability of the human respiratory syncytial virus F glycoprotein compared to related viruses in a comprehensive dataset , 2018, Vaccine.

[14]  F. Alt,et al.  Glycan Masking Focuses Immune Responses to the HIV‐1 CD4‐Binding Site and Enhances Elicitation of VRC01‐Class Precursor Antibodies , 2018, Immunity.

[15]  L. Kauvar,et al.  Structures of respiratory syncytial virus G antigen bound to broadly neutralizing antibodies , 2018, Science Immunology.

[16]  A. Sivasubramanian,et al.  Infants Infected with Respiratory Syncytial Virus Generate Potent Neutralizing Antibodies that Lack Somatic Hypermutation , 2018, Immunity.

[17]  M. Kanekiyo,et al.  Structural basis of respiratory syncytial virus subtype-dependent neutralization by an antibody targeting the fusion glycoprotein , 2017, Nature Communications.

[18]  J. McLellan,et al.  Clinical Potential of Prefusion RSV F-specific Antibodies. , 2017, Trends in microbiology.

[19]  B. Graham,et al.  Discovery of a Prefusion Respiratory Syncytial Virus F-Specific Monoclonal Antibody That Provides Greater In Vivo Protection than the Murine Precursor of Palivizumab , 2017, Journal of Virology.

[20]  N. Patel,et al.  A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants , 2017, Science Translational Medicine.

[21]  R. Lamb,et al.  Structural basis for antibody cross-neutralization of respiratory syncytial virus and human metapneumovirus , 2017, Nature Microbiology.

[22]  B. Graham,et al.  Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors , 2016, Science Immunology.

[23]  P. Collins,et al.  Structure and Function Analysis of an Antibody Recognizing All Influenza A Subtypes , 2016, Cell.

[24]  F. V. van Kuppeveld,et al.  Characterization of Epitope-Specific Anti-Respiratory Syncytial Virus (Anti-RSV) Antibody Responses after Natural Infection and after Vaccination with Formalin-Inactivated RSV , 2016, Journal of Virology.

[25]  Changgui Li,et al.  A Recombinant G Protein Plus Cyclosporine A–Based Respiratory Syncytial Virus Vaccine Elicits Humoral and Regulatory T Cell Responses against Infection without Vaccine-Enhanced Disease , 2016, The Journal of Immunology.

[26]  D. Burton,et al.  Identification of Common Features in Prototype Broadly Neutralizing Antibodies to HIV Envelope V2 Apex to Facilitate Vaccine Design. , 2015, Immunity.

[27]  G. Chuang,et al.  Prefusion F–specific antibodies determine the magnitude of RSV neutralizing activity in human sera , 2015, Science Translational Medicine.

[28]  Sharada M. Potukuchi,et al.  Comparative sequence- and structure-inspired drug design for PilF protein of Neisseria meningitidis , 2015, Human Genomics.

[29]  Michael P. McCarthy,et al.  Palivizumab epitope-displaying virus-like particles protect rodents from RSV challenge. , 2015, The Journal of clinical investigation.

[30]  Julien Sourimant,et al.  Visualizing the replication of respiratory syncytial virus in cells and in living mice , 2014, Nature Communications.

[31]  R. Sanders,et al.  Targeting B-cell germlines and focusing affinity maturation: the next hurdles in HIV-1-vaccine development? , 2014, Expert review of vaccines.

[32]  A. Falsey,et al.  Respiratory Syncytial Virus and Other Respiratory Viral Infections in Older Adults With Moderate to Severe Influenza-like Illness , 2014, The Journal of infectious diseases.

[33]  Cinque S. Soto,et al.  Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus , 2013, Science.

[34]  U. Baxa,et al.  Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody , 2013, Science.

[35]  P. Kwong,et al.  Structure of a Major Antigenic Site on the Respiratory Syncytial Virus Fusion Glycoprotein in Complex with Neutralizing Antibody 101F , 2010, Journal of Virology.

[36]  P. Kwong,et al.  Structural basis of respiratory syncytial virus neutralization by motavizumab , 2010, Nature Structural &Molecular Biology.

[37]  J. Wrammert,et al.  Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen , 2009, Nature Protocols.

[38]  Jeffrey J. Gray,et al.  Modeling the structure of mAb 14B7 bound to the anthrax protective antigen , 2007, Proteins.

[39]  O. Ramilo,et al.  Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. , 1998, The Journal of infectious diseases.

[40]  A. Sominina,et al.  [Characteristics of monoclonal antibodies to RS virus in immunoenzyme and immunofluorescence techniques]. , 1995, Vestnik Rossiiskoi akademii meditsinskikh nauk.